ReviewExpert opinion on drug metabolism & toxicology2021
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
Review in Expert opinion on drug metabolism & toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Personalizing Liposomal Paclitaxel in Platinum-Based Combination Therapy for Gynecologic Cancers: Defining a Therapeutic Window Based on TcEuropean journal of drug metabolism and pharmacokinetics · 2026Article
- Prevalence and predictive testing preferences for breast cancer treatment side effects.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Pharmacokinetic-Pharmacodynamic Model of Paclitaxel-Induced Peripheral Neuropathy.Clinical and translational science · 2025Article
- Review of the contribution of clinical and genetic factors to the racial disparity in taxane-induced peripheral neuropathy.Critical reviews in oncology/hematology · 2025Review
- Neurotoxicity associated with cancer chemotherapy: the first study in the Palestinian healthcare system.BMC cancer · 2025Article
- Using maximum plasma concentration (CCancer chemotherapy and pharmacology · 2024Review
- Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.European journal of cancer (Oxford, England : 1990) · 2024Review
- [Peripheral neuropathy, onycholysis and health-related quality of life in womens with breast cancer treated with taxanes. Prospective longitudinal study.]Revista espanola de salud publica · 2023Article
- Modern developments in germline pharmacogenomics for oncology prescribing.CA: a cancer journal for clinicians · 2022Review
- Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing.British journal of clinical pharmacology · 2022Article
- Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.Pharmacogenomics and personalized medicine · 2022Review
- Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.Methods in molecular biology (Clifton, N.J.) · 2022Review
- Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.